AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1.-45. (canceled)

46. (new) A method for enhancing an immune response to an antigen in an individual to which said antigen is administered comprising administering to said individual an amount, effective to enhance said immune response, of a composition comprising a saponin adjuvant and an excipient, said excipient being selected from the group consisting of a β cyclodextrin, a human serum albumin, a deacylsaponin, and a nonionic surfactant.

47. (new) The method of claim 46, wherein the saponin adjuvant is a heterogeneous saponin adjuvant.

48. (new) The method of claim 47, wherein the heterogenous saponin adjuvant is Quil-A.

49. (new) The method of claim 46, wherein the saponin adjuvant comprises two or more substantially pure saponins selected from the group consisting of QS-7, QS-17, QS-18, QS-21, and QS-21.

50. (new) The method of claim 46, wherein the saponin adjuvant is a substantially pure saponin adjuvant.

51. (new) The method of claim 50, wherein the substantially pure saponin adjuvant is selected from the group of QS-7, QS-17, QS-18 and QS-21.

52. (new) The method of claim 50, wherein the substantially pure saponin adjuvant is QS-21.

53. (new) The method of claim 50, wherein the substantially pure saponin adjuvant is QS-7.

54. (new) The method of claim 46, wherein the antigen is a peptide, a protein, a polysaccharide, a lipid, or a nucleic acid.

55. The composition according to claim 46, wherein the excipient is a nonionic surfactant.

56. (new) The composition according to claim 55, wherein the nonionic surfactant is a Polysorbate.

57. (new) The composition according to claim 56, wherein the Polysorbate is Polysorbate 20, Polysorbate 40, Polysorbate 60, or Polysorbate 80.

58. (new) The composition according to claim 46, wherein the excipient is β-cyclodextrin.

59. (new) The composition according to claim 58, wherein the β- cyclodextrin is hydroxypropyl- β- cyclodextrin.

60. (new) The method of claim 46, wherein the excipient is a human serum albumin.

61. (new) The method of claim 46, wherein the excipient is a deacylsaponin ("DS").

62. (new) The method of claim 61, wherein the excipient is DS-1.

63. (new) The method of claim 46, wherein said antigen and said composition are administered to said individual concurrently.

64. (new) The method of claim 46, wherein said individual is a mammal.

65. (new) The method of claim 64, wherein said individual is a human.